Targeted Therapies for Colorectal Cancer

摘要: In the last decades, standard chemotherapeutic approach for metastatic colorectal cancer (mCRC) treatment was represented by a 5-FU-based regimen with addition of either oxaliplatin or irinotecan. Recent discoveries in molecular biology field led to spread so-called targeted agents whose mechanism action is based on binding specific target molecules (cellular receptors soluble proteins) responsible activation many transduction pathways required malignant cell growth and survival. Among these, most important consist monoclonal antibodies (mAbs) tyrosine kinase inhibitors (TKIs). As consequence, different these new drugs involves variability improved outcomes achieved tolerability profile. These chemotherapy options will represent next future milestone biological era mCRC patients.